At two upcoming events, experts will offer practical solutions to key challenges for oncology and rare disease clinical trials.

In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.

Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.

Johnson & Johnson has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a deal valued at $3.05bn in cash.

The FDA’s verdict on Poherdy comes amid Perjeta creator Genentech’s patent infringement lawsuit against Organon and Shanghai Henlius Biotech.

A CHMP panel has recommended the high-dose version’s approval, countering an FDA rejection for the drug in recent months.

Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused biotechnology companies. The firm will also consider assisting existing companies no ...

The fund will participate in follow-on and initial rounds, focusing on biotech and medtech ventures across core markets.

The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming patent expiry.

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for market share.